Nicox S.A. Acquires Aciex Therapeutics, Inc.
July 2, 2014
Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.
- Buyers
- Nicox S.A.
- Targets
- Aciex Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
July 9, 2026
Biotechnology
Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.
-
ACEA Therapeutics and ACEA Pharma to Acquire Phoenix Asia Holdings’ ACEA Pharma Stake in $1B Stock Deal
May 5, 2026
Pharmaceuticals
Scilex Holding Company’s indirect subsidiaries ACEA Therapeutics, Inc. and ACEA Pharma, Inc. entered into a stock acquisition agreement with Phoenix Asia Holdings Limited to acquire 100% of ACEA Pharma. The transaction is valued at $1 billion and will issue Phoenix shares to ACEA Therapeutics, with Phoenix expected to be renamed the “Go-Forward Company” ACEA Pharma and listed on Nasdaq after closing.
-
Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights
October 15, 2025
Pharmaceuticals
Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.
-
ABIONYX Pharma Acquires IRIS Pharma via Contribution in Kind
December 6, 2021
Biotechnology
ABIONYX Pharma completed a contribution in kind of 100% of the capital of IRIS Pharma Holding, issuing new ABIONYX shares at €3.60 per share to acquire the business. IRIS Pharma will become a subsidiary of ABIONYX while remaining operationally independent as a specialist CRO in ophthalmology, providing ABIONYX with ophthalmology R&D capabilities and a potential portfolio of biologic candidates.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics
August 31, 2020
Biotechnology
Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.